Oculus Innovative Sciences Inc.

Hojabr Alimi , one of our founders, has served as our Chief Executive Officer, President and director since 1999 and was appointed as Chairman of the board of directors in June 2006. Prior to co-founding our company with his spouse in 1999, Mr. Alimi was a Corporate Microbiologist for Arterial Vascular Engineering. Mr. Alimi received a B.A. in biology from Sonoma State University.

Bruce Thornton has served as our vice president of international operations and sales since June 2005. Mr. Thornton served as our general manager for U.S. operations from March 2004 to July 2005. He served as vice president of operations for Jomed (formerly EndoSonic Corp.) from January 1999 to September 2003, and as vice president of manufacturing for Volcano Therapeutics, an international medical device company, following its acquisition of Jomed, until March 2004. Mr. Thornton received a B.S. in aeronautical science from Embry-Riddle Aeronautical University and an M.B.A. from National University.

James Schutz has served as our vice president of corporate development and general counsel since August 2003, as a director since May 2004 and corporate secretary since June 2006. From August 2001 to August 2003, Mr. Schutz served as general counsel at Jomed (formerly EndoSonic Corp.), an international medical device company. From 1999 to July 2001, Mr. Schutz served as in-house counsel at Urban Media Communications Corporation, an Internet/telecom company based in Palo Alto, California. Mr. Schutz received a B.A. in economics from the University of California, San Diego and a J.D. from the University of San Francisco School of Law.

Robert Northey, Ph.D. has served as our director of research and development since July 2005. Dr. Northey served as a consultant to us from May 2001 to June 2005. From August 1998 until June 2005, he was an assistant professor in the paper science and engineering department at the University of Washington. Dr. Northey received a B.S. in wood and fiber science and a Ph.D. in wood chemistry, each from the University of Washington.

Gregory French has served as a director since 2000. Mr. French is owner and chairman of the board of G&C Enterprises LLC, a real estate and investment company, which he founded in 1999. He held various engineering and senior management positions at several medical device companies, including Advanced Cardiovascular Systems, Peripheral Systems Group and Arterial Vascular Engineering. Mr. French received a B.S.I.E. from the California State Polytechnic University, San Luis Obispo.

Gregg Alton has served as a director since January 2008. Mr. Alton is currently a senior vice president, general counsel and secretary at Gilead Sciences, Inc. His expertise lies in the areas legal affairs, public affairs, government affairs, and international access operations of publicly traded biopharmaceutical company. In addition, Mr. Alton is a member and chairman of Gilead Healthcare PAC, and a member of the board of Gilead Foundation. Since joining Gilead Sciences Inc. as associate general counsel in 1999, Mr. Alton has managed the company's departments of U.S. and European legal affairs; intellectual property; public affairs; international access operations; government affairs; and global government affairs. Previously, Mr. Alton was a corporate associate at the mergers and acquisitions group Cooley Godward LLP, where he counseled technology and biotechnology clients in transaction structures and related documentation. Prior to that, Mr. Alton served a similar role as a corporate associate at Mintz, Levin, Cohn, Ferris, Glovsky & Popeco. He received a BA in legal studies from the University of California at Berkeley, and a JD from Stanford Law School.

Jay Birnbaum has served as a director since April 2007. Dr. Birnbaum is a pharmacologist and previous to his current role as a consultant to pharmaceutical companies, he served as vice president of global project management at Novartis/Sandoz Pharmaceuticals Corporation, where he had responsibility for strategic planning and development of the company's dermatology portfolio. Dr. Birnbaum is a co-founder of Kythera Biopharmaceuticals, a company developing products in aesthetic and restorative dermatology, as well as a member of NanoBio Corporation's scientific advisory board. He received both an M.S. and Ph.D. in pharmacology from the University of Wisconsin and a B.S. in biology from Trinity College in Connecticut.

Dr. Schnur is past chairman of the division of plastic surgery, Mayo Clinic Arizona. He is past president of The American Society of Plastic Surgeons and Associate Professor of Plastic Surgery at Mayo Medical School and University of Arizona College of Medicine.

Richard Conley has served as a director since 1999, and served as our secretary from July 2002 to June 2006. Since April 2001, Mr. Conley has served as executive vice president and chief operating officer at Don Sebastiani & Sons International Wine Negociants, a branded wine marketing company. From 1994 to March 2001, he served as senior vice president and chief operating officer at Sebastiani Vineyards, a California wine producer, where he was originally hired as chief financial officer in 1994. Mr. Conley received a B.S. in finance and accounting from Western Carolina University and an M.B.A. from St. Mary's University.

Robert Burlingame has served as a director since November 2006. Mr. Burlingame is the chief executive officer and chairman of the board of Burlingame Industries, Inc., a manufacturer of automated equipment specializing in the concrete rooftile industry, which he founded in 1969. He has held various senior management positions at several rooftile companies, including California Tile and Lifetile Corporation. Mr. Burlingame received a B.S. in business from Michigan State University and was a pilot in the U.S. Navy.